Literature DB >> 31115195

Molecular Genetics of Noonan Syndrome and RASopathies.

Jun Liao1, Lakshmi Mehta2.   

Abstract

The RAS/MAPK signaling pathway plays an essential role in development and tumorigenesis by regulating cell proliferation, differentiation, apoptosis, migration, and metabolism. Therefore, it is not surprising that germline mutations in genes encoding components or regulators of this signaling pathway cause numerous human genetic conditions, including Noonan syndrome and related disorders. The term "RASopathies" has been used to describe these disorders collectively due to their common underlying RAS/MAPK pathway dysregulation and overlapping clinical features. Taken together, the RASopathies represent one of the most common groups of genetic disorders, affecting approximately 1 in 1,000 individuals. This review describes the RAS/MAPK signaling pathway, summarizes multiple molecular genetic approaches used during the last several decades to discover genes responsible for different RASopathies, and finally focuses on several major disease genes associated with Noonan syndrome and related disorders with regard to genomic locations, structure, mutations, and genotype-phenotype correlations. Copyright© of YS Medical Media ltd.

Entities:  

Keywords:  MAPK pathway; Molecular Genetics; Noonan; PTPN11; Rasopathies

Mesh:

Substances:

Year:  2019        PMID: 31115195     DOI: 10.17458/per.vol16.2019.lm.molecularnoonan

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  2 in total

1.  Chiari 1 malformation and exome sequencing in 51 trios: the emerging role of rare missense variants in chromatin-remodeling genes.

Authors:  Aldesia Provenzano; Andrea La Barbera; Mirko Scagnet; Angelica Pagliazzi; Giovanna Traficante; Marilena Pantaleo; Lucia Tiberi; Debora Vergani; Nehir Edibe Kurtas; Silvia Guarducci; Sara Bargiacchi; Giulia Forzano; Rosangela Artuso; Viviana Palazzo; Ada Kura; Flavio Giordano; Daniele di Feo; Marzia Mortilla; Claudio De Filippi; Gianluca Mattei; Livia Garavelli; Betti Giusti; Lorenzo Genitori; Orsetta Zuffardi; Sabrina Giglio
Journal:  Hum Genet       Date:  2020-12-18       Impact factor: 4.132

Review 2.  Growth, Endocrine Features, and Growth Hormone Treatment in Noonan Syndrome.

Authors:  Jovanna Dahlgren; Cees Noordam
Journal:  J Clin Med       Date:  2022-04-05       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.